De-Regil Luz Maria, Palacios Cristina, Lombardo Lia K, Peña-Rosas Juan Pablo
Research and Evaluation, Micronutrient Initiative, 180 Elgin Street, Suite 1000, Ottawa, ON, Canada, K2P 2K3.
Cochrane Database Syst Rev. 2016 Jan 14(1):CD008873. doi: 10.1002/14651858.CD008873.pub3.
Vitamin D deficiency or insufficiency is thought to be common among pregnant women. Vitamin D supplementation during pregnancy has been suggested as an intervention to protect against adverse pregnancy outcomes.
To examine whether oral supplements with vitamin D alone or in combination with calcium or other vitamins and minerals given to women during pregnancy can safely improve maternal and neonatal outcomes.
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (23 February 2015), the International Clinical Trials Registry Platform (31 January 2015), the Networked Digital Library of Theses and Dissertations (28 January 2015) and also contacted relevant organisations (31 January 2015).
Randomised and quasi-randomised trials with randomisation at either individual or cluster level, evaluating the effect of supplementation with vitamin D alone or in combination with other micronutrients for women during pregnancy.
Two review authors independently i) assessed the eligibility of studies against the inclusion criteria ii) extracted data from included studies, and iii) assessed the risk of bias of the included studies. Data were checked for accuracy. The quality of the evidence was assessed using the GRADE approach.
In this updated review we included 15 trials assessing a total of 2833 women, excluded 27 trials, and 23 trials are still ongoing or unpublished. Nine trials compared the effects of vitamin D alone versus no supplementation or a placebo and six trials compared the effects of vitamin D and calcium with no supplementation. Risk of bias in the majority of trials was unclear and many studies were at high risk of bias for blinding and attrition rates. Vitamin D alone versus no supplementation or a placebo Data from seven trials involving 868 women consistently show that women who received vitamin D supplements alone, particularly on a daily basis, had higher 25-hydroxyvitamin D than those receiving no intervention or placebo, but this response was highly heterogeneous. Also, data from two trials involving 219 women suggest that women who received vitamin D supplements may have a lower risk of pre-eclampsia than those receiving no intervention or placebo (8.9% versus 15.5%; risk ratio (RR) 0.52; 95% CI 0.25 to 1.05, low quality). Data from two trials involving 219 women suggest a similar risk of gestational diabetes among those taking vitamin D supplements or no intervention/placebo (RR 0.43; 95% CI 0.05, 3.45, very low quality). There were no clear differences in adverse effects, with only one reported case of nephritic syndrome in the control group in one study (RR 0.17; 95% CI 0.01 to 4.06; one trial, 135 women, low quality). Given the scarcity of data for this outcome, no firm conclusions can be drawn. No other adverse effects were reported in any of the other studies.With respect to infant outcomes, data from three trials involving 477 women suggest that vitamin D supplementation during pregnancy reduces the risk preterm birth compared to no intervention or placebo (8.9% versus 15.5%; RR 0.36; 95% CI 0.14 to 0.93, moderate quality). Data from three trials involving 493 women also suggest that women who receive vitamin D supplements during pregnancy less frequently had a baby with a birthweight below 2500 g than those receiving no intervention or placebo (RR 0.40; 95% CI 0.24 to 0.67, moderate quality).In terms of other outcomes, there were no clear differences in caesarean section (RR 0.95; 95% CI 0.69 to 1.31; two trials; 312 women); stillbirths (RR 0.35 95% CI 0.06, 1.99; three trials, 540 women); or neonatal deaths (RR 0.27; 95% CI 0.04, 1.67; two trials, 282 women). There was some indication that vitamin D supplementation increases infant length (mean difference (MD) 0.70, 95% CI -0.02 to 1.43; four trials, 638 infants) and head circumference at birth (MD 0.43, 95% CI 0.03 to 0.83; four trials, 638 women). Vitamin D and calcium versus no supplementation or a placeboWomen who received vitamin D with calcium had a lower risk of pre-eclampsia than those not receiving any intervention (RR 0.51; 95% CI 0.32 to 0.80; three trials; 1114 women, moderate quality), but also an increased risk of preterm birth (RR 1.57; 95% CI 1.02 to 2.43, three studies, 798 women, moderate quality). Maternal vitamin D concentration at term, gestational diabetes, adverse effects and low birthweight were not reported in any trial or reported only by one study.
AUTHORS' CONCLUSIONS: New studies have provided more evidence on the effects of supplementing pregnant women with vitamin D alone or with calcium on pregnancy outcomes. Supplementing pregnant women with vitamin D in a single or continued dose increases serum 25-hydroxyvitamin D at term and may reduce the risk of pre-eclampsia, low birthweight and preterm birth. However, when vitamin D and calcium are combined, the risk of preterm birth is increased. The clinical significance of the increased serum 25-hydroxyvitamin D concentrations is still unclear. In light of this, these results need to be interpreted with caution. Data on adverse effects were lacking in all studies.The evidence on whether vitamin D supplementation should be given as a part of routine antenatal care to all women to improve maternal and infant outcomes remains unclear. While there is some indication that vitamin D supplementation could reduce the risk of pre-eclampsia and increase length and head circumference at birth, further rigorous randomised trials are required to confirm these effects.
维生素D缺乏或不足在孕妇中被认为很常见。孕期补充维生素D被建议作为一种预防不良妊娠结局的干预措施。
研究孕期单独给女性补充维生素D或与钙或其他维生素及矿物质联合补充,是否能安全改善母婴结局。
我们检索了Cochrane妊娠与分娩组试验注册库(2015年2月23日)、国际临床试验注册平台(2015年1月31日)、学位论文网络数字图书馆(2015年1月28日),并在2015年1月31日联系了相关组织。
个体或整群随机化的随机和半随机试验,评估孕期单独补充维生素D或与其他微量营养素联合补充的效果。
两位综述作者独立进行:i)根据纳入标准评估研究的合格性;ii)从纳入研究中提取数据;iii)评估纳入研究的偏倚风险。检查数据的准确性。使用GRADE方法评估证据质量。
在本次更新的综述中,我们纳入了15项评估共2833名女性的试验,排除了27项试验,还有23项试验仍在进行或未发表。9项试验比较了单独补充维生素D与不补充或安慰剂的效果,6项试验比较了补充维生素D和钙与不补充的效果。大多数试验的偏倚风险不明确,许多研究在盲法和失访率方面存在高偏倚风险。单独补充维生素D与不补充或安慰剂:涉及868名女性的7项试验数据一致显示,单独接受维生素D补充剂的女性,尤其是每日补充的,其25-羟维生素D水平高于未接受干预或安慰剂的女性,但这种反应高度异质性。此外,涉及219名女性的2项试验数据表明,接受维生素D补充剂的女性患先兆子痫的风险可能低于未接受干预或安慰剂的女性(8.9%对15.5%;风险比(RR)0.52;95%置信区间0.25至1.05,低质量)。涉及219名女性的2项试验数据表明,服用维生素D补充剂的女性与未接受干预/安慰剂的女性患妊娠期糖尿病的风险相似(RR 0.43;95%置信区间0.05,3.45,极低质量)。不良反应方面无明显差异,一项研究中对照组仅报告了1例肾病综合征病例(RR 0.17;95%置信区间0.01至4.06;一项试验,135名女性,低质量)。鉴于该结局的数据稀缺,无法得出确切结论。其他研究均未报告其他不良反应。关于婴儿结局,涉及477名女性的3项试验数据表明,孕期补充维生素D与未干预或安慰剂相比可降低早产风险(8.9%对15.5%;RR 0.36;95%置信区间0.14至0.93,中等质量)。涉及493名女性的3项试验数据还表明,孕期接受维生素D补充剂的女性生出出生体重低于2500g婴儿的频率低于未接受干预或安慰剂的女性(RR 0.40;95%置信区间0.24至0.67,中等质量)。在其他结局方面,剖宫产(RR 0.95;95%置信区间0.69至1.31;2项试验;312名女性)、死产(RR 0.35,95%置信区间0.06,1.99;3项试验,540名女性)或新生儿死亡(RR 0.27;95%置信区间0.04,1.67;2项试验,282名女性)方面无明显差异。有迹象表明补充维生素D可增加婴儿出生时的身长(平均差(MD)0.70,95%置信区间-0.02至1.43;4项试验,638名婴儿)和头围(MD 0.43,95%置信区间0.03至0.83;4项试验,638名女性)。补充维生素D和钙与不补充或安慰剂:接受维生素D和钙的女性患先兆子痫的风险低于未接受任何干预的女性(RR 0.51;95%置信区间0.32至0.80;3项试验;1114名女性,中等质量),但早产风险也增加(RR 1.57;95%置信区间1.02至2.43,3项研究,798名女性,中等质量)。足月时的母体维生素D浓度、妊娠期糖尿病、不良反应和低出生体重在任何试验中均未报告或仅在一项研究中报告。
新的研究提供了更多关于孕期单独补充维生素D或与钙联合补充对妊娠结局影响的证据。单次或持续给孕妇补充维生素D可增加足月时血清25-羟维生素D水平,并可能降低先兆子痫、低出生体重和早产的风险。然而,维生素D与钙联合补充时,早产风险增加。血清25-羟维生素D浓度升高的临床意义仍不明确。鉴于此,这些结果需谨慎解读。所有研究均缺乏不良反应数据。关于是否应将补充维生素D作为所有女性常规产前护理的一部分以改善母婴结局的证据仍不明确。虽然有迹象表明补充维生素D可降低先兆子痫风险并增加出生时的身长和头围,但需要进一步严格的随机试验来证实这些效果。